Roche acquires Genentech (2009)
Swiss pharmaceutical company Roche completed a $46.8 billion acquisition of the 44 percent of Genentech it did not already own, fully absorbing the pioneering biotech company. The deal was the largest in the pharmaceutical industry at the time and aimed to combine Roche's global commercial reach with Genentech's innovative drug discovery pipeline.
Genentech's South San Francisco operations were preserved as a semi-autonomous unit, and most key scientists stayed. Roche gained full control of blockbuster cancer drugs including Avastin and Herceptin.
The deal validated the strategy of large life sciences companies acquiring specialized capabilities rather than building them internally. Roche's pipeline remained productive for years, though Genentech's independent culture was gradually diluted.
Like Roche's bet on Genentech, Thermo Fisher is acquiring a company whose value lies in specialized expertise and client relationships that are difficult to replicate. The key risk in both cases is whether the acquired company's capabilities survive integration into a much larger organization.